3 Covid shots make good response in under-5s: Pfizer-BioNTech

3 Covid shots make good response in under-5s: Pfizer-BioNTech

According to a preliminary estimate, Pfizer’s efficiency was 80.3 percent. (Representative)


The companies said in a statement Monday that the Pfizer-Biotech Covid vaccine is safe and effective for children under the age of six months to five years.

The announcement comes as the US Food and Drug Administration (FDA) plans to hold a meeting in the coming weeks to approve the covid vaccine among the youngest children, the only age group that is still not eligible in most countries, causing concern among many parents. .

Pfizer-BioNTech evaluated three doses given in three micrograms in a clinical trial and the vaccine produced a strong immune response. Side effects were similar in the vaccine and placebo groups.

According to a preliminary estimate, the effectiveness of the vaccine was 80.3 percent.

Albert Borla, CEO of Pfizer, said in a statement: “We are pleased that our formulation for the youngest child, which we carefully selected as a tenth of the dose energy for adults, was well tolerated and developed a strong immune system.”

“We look forward to submitting our report to regulators worldwide as soon as possible, subject to regulatory approval, with the hope of making it available to young children as soon as possible.”

The FDA has temporarily set three dates in June where experts will meet and possibly decide whether to approve the Pfizer Covid vaccine for those under five and the Moderna vaccine for those under six, given as two shots of 25 micrograms.

The agency was originally set to evaluate the two-dose Pfizer vaccine in February, but data showed that it did not provoke a strong immune response in children between the ages of two and four. The FDA then asks to see the data for the third shot.

(Except for the title, this story was not edited by NDTV staff and was published from a syndicated feed.)

Related Posts

Leave a Reply

Your email address will not be published.